BL Corp
KOSDAQ:142760
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BL Corp
Net Income (Common)
BL Corp
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BL Corp
KOSDAQ:142760
|
Net Income (Common)
-₩11.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Net Income (Common)
₩1T
|
CAGR 3-Years
24%
|
CAGR 5-Years
15%
|
CAGR 10-Years
22%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Net Income (Common)
-₩15.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Net Income (Common)
-₩32.6B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Net Income (Common)
₩141.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
61%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Net Income (Common)
-₩37.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
BL Corp
Glance View
BL Corp. engages in the development of biopharmaceutical products. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2014-11-26. The firm is engaged in the manufacture and sale of health functional foods and functional cosmetics. In addition, the Company is engaged in the distribution of pharmaceuticals and medical supplies. The firm is engaged in the distribution of Glu 100 Tablets, CellribonQ, and GentaQ and other medicine to general hospitals and pharmacies.
See Also
What is BL Corp's Net Income (Common)?
Net Income (Common)
-11.8B
KRW
Based on the financial report for Sep 30, 2025, BL Corp's Net Income (Common) amounts to -11.8B KRW.
What is BL Corp's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
14%
The average annual Net Income (Common) growth rates for BL Corp have been 23% over the past three years , 14% over the past five years .
